Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-06-19 am EDT			5-day change	1st Jan Change
984.2 ^DKK	+0.31%		-0.55%	+40.98%

04:15pm	Novo Nordisk says no sign of crime, links between fires at Denmark facilities	RE
11:59am	Novo Nordisk says no sign of crime, links between fires at Denmark facilities	RE

NOVO NORDISK : UBS drops its Sell rating

January 15, 2024 at 03:14 pm EST

UBS's analyst Jo Walton upgraded the rating on the company from Sell to Neutral. The target price has been raised to DKK 795 from DKK 360.

Latest news about Novo Nordisk A/S

Novo Nordisk says no sign of crime, links between fires at Denmark facilities	10:15am	RE
Novo Nordisk says no sign of crime, links between fires at Denmark facilities	05:59am	RE
Novo Nordisk Says Fire at Denmark Building Under Control	11:57pm	MT
Novo Nordisk Office Near Copenhagen Headquarters Hit by Fire	Jun. 18	DJ
A weight loss ETF	Jun. 18	MT
Novo Nordisk to present 34 abstracts at ADA	Jun. 18	CF
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup	Jun. 17	DJ
Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovy in US Senate Hearing	Jun. 17	MT
Weight-loss options for US youth are hard to come by	Jun. 17	RE
Novo Nordisk CEO Agrees to US Senate Committee Testimony to Address 'Outrageously High' Ozempic, Wegovy Prices	Jun. 17	MT
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy	Jun. 14	RE
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	Jun. 14	DJ
Novo Nordisk: study results for hemophilia A	Jun. 14	CF
NOVO NORDISK : Deutsche Bank reiterates its Buy rating	Jun. 14	ZD
Second Chinese drugmaker seeks approval for Ozempic generic	Jun. 13	RE
Employer coverage for weight-loss drugs rises sharply, survey finds	Jun. 13	RE
IVivani Medical Gets FDA Clearance to Start Trial of GLP-1 Implant for Diabetes	Jun. 13	DJ
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan	Jun. 12	MT
Global markets live: Apple, Oracle, Amazon, Boeing, Tesla...	Jun. 12
Health Care Down as Rally Pauses -- Health Care Roundup	Jun. 11	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Jun. 11	MT
Novo Nordisk to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices	Jun. 11	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Jun. 11	MT
Sector Update: Health Care	Jun. 11	MT
Novo Nordisk President to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices	Jun. 11	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-06-22 - American Diabetes Association Scientific Conference

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 12:36 pm EDT

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 12:09 pm EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

981.2 DKK

Average target price

934.3 DKK

Spread / Average Target

-4.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+40.98%	629B
ELI LILLY AND COMPANY	+52.93%	803B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.42%	244B
ROCHE HOLDING AG	+2.17%	226B
NOVARTIS AG	+10.66%	215B
AMGEN INC.	+6.24%	164B
PFIZER, INC.	-4.79%	155B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : UBS drops its Sell rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals